Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Turn Therapeutics Inc.NASDAQ: TTRX
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit of -$14.45K in Q1 FY2026
Q1 FY2026 gross profit was -$14.45K. Trailing-twelve-month gross profit was -$42.29K.
Context
- Gross profit increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$14.45K or moves back toward the trailing-twelve-month quarterly average of -$10.57K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Gross Profit vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 gross profit of -$42.29K is the 8th highest of the 9 companies compared; the peer median is -$438.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.58M | +289.3% | — | 52.1% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $5.95M | +1.3% | -29.1% | 49.6% |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| LTM Mar 2026 | -$876 | +75.7% | — | — | |
| LTM Apr 2026 | -$9K | — | — | — | |
| LTM Mar 2026 | -$23.47K | +63.1% | — | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$42.29K | — | — | — |
| LTM Mar 2026 | -$129K | — | — | — | |
| Peer median (excluding TTRX) | -$438 | +69.4% | +20.7% | 49.6% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 7.5K | 245.96K | 265.57K |
| Selling, General & Admin | 2.3M | 1.55M | 5.59M |
| Operating Expenses | 2.31M | 1.8M | 5.86M |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| EBITDA | (2.25M) | (1.72M) | (3.14M) |
| EBITDA Margin | — | — | — |
| Operating Income | (2.31M) | (1.8M) | (5.86M) |
| Operating Margin | — | — | — |
| Interest Income | 15.88K | 28.71K | 29.58K |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 15.88K | 28.71K | 2.66M |
| Income Before Tax | (2.29M) | (1.77M) | (3.19M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.17) | (0.13) | (0.23) |
| EPS (Diluted) | (0.17) | (0.13) | (0.23) |
| Weighted Avg Shares | 13.25M | 13.42M | 13.74M |
| Weighted Avg Shares (Diluted) | 13.25M | 13.42M | 13.74M |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.